Brought to you by 
Series B round brings in $38.5mm for Atara Biotherapeutics; closed at $52mm
15 Jul 2014
Executive Summary
Cancer and renal disease drug developer Atara Biotherapeutics Inc. raised $38.5mm through its Series B financing. Amgen Ventures, Celgene Corp., and crossover fund EcoR1 Capital joined current shareholders Alexandria Venture Investments (AVI), DAG Ventures, Domain Associates, and Kleiner Perkins Caufield & Byers. (AVI gains representation on Atara’s board.) The round is still open and Atara hopes to add one more investor within 90 days.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B round brings in $38.5mm for Atara Biotherapeutics; closed at $52mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice